Myostatin is a signalling protein involved in the regulation of skeletal muscle biology. Also known as growth differentiation factor 8, or GDF-8, it is encoded by the MSTN gene and belongs to the transforming growth factor beta superfamily.
Its biology involves several distinct molecular stages.
Myostatin is first produced as a larger precursor. It then undergoes proteolytic processing, forms a latent complex and requires further activation before the mature ligand becomes available for receptor interaction.
Researchers study each of these stages separately. This makes it possible to investigate not only myostatin itself, but also the molecular processes that determine when and how it becomes active.
This article focuses on myostatin formation, latency, extracellular activation, endogenous regulation and the different experimental approaches used to investigate myostatin inhibition.
Stages of Myostatin Regulation
| Stage | What happens | Main research focus |
|---|---|---|
| MSTN expression | The MSTN gene is transcribed and translated | Gene regulation and expression |
| Precursor formation | Myostatin is produced as prepro-myostatin | Protein synthesis and processing |
| Furin cleavage | The precursor is cleaved into prodomain and mature regions | Proteolytic processing |
| Latent complex formation | The prodomain remains associated with mature myostatin | Regulation of ligand availability |
| Extracellular activation | Further proteolysis makes mature myostatin available | BMP-1/tolloid-family enzymes |
| Endogenous regulation | Binding proteins influence ligand availability | Follistatin, FSTL3 and related regulators |
| Experimental inhibition | Researchers interfere with specific stages | Activation blockade and ligand-binding studies |
What Is Myostatin?
Myostatin, also known as GDF-8, is a TGF-β-superfamily signalling protein encoded by the MSTN gene and studied for its role in skeletal muscle biology.
Myostatin is a secreted protein belonging to the TGF-β superfamily of signalling molecules.
These early findings made myostatin an important experimental target.
They also raised another question: how does the protein progress from gene expression to an active extracellular signalling molecule?
The answer involves several stages of protein processing.
How Is Myostatin Produced?
Myostatin is initially synthesised as a larger precursor known as prepro-myostatin.
This precursor contains three main regions:
- a signal peptide
- an N-terminal prodomain
- a C-terminal growth-factor domain
The signal peptide directs the newly synthesised protein through the secretory pathway.
Once the signal sequence has been removed, further processing occurs at a furin cleavage site. This separates the prodomain from the C-terminal region that will form mature myostatin.
However, cleavage does not immediately result in freely available active myostatin.
The prodomain remains associated with the mature growth-factor region.
This creates another regulatory stage.
What Is Latent Myostatin?
Latent myostatin is mature myostatin associated with its prodomain, which restricts the ligand's availability until further molecular processing occurs.
Following initial processing, mature myostatin can remain associated with its prodomain.
The resulting structure is known as a latent complex.
Association with the prodomain restricts the availability of mature myostatin for receptor interaction. Myostatin can therefore be present extracellularly without necessarily being available for signalling in the same form.
This distinction is important when interpreting experimental measurements.
Depending on the analytical method used, researchers may detect:
- precursor myostatin
- latent myostatin
- mature myostatin
- or more than one molecular form
A measurement described simply as “myostatin concentration” therefore needs to be interpreted alongside the method and molecular form being measured.
How Does Latent Myostatin Become Active?
Latent myostatin can become more available following prodomain cleavage involving BMP-1/tolloid-family metalloproteinases such as BMP-1, TLL-1 and TLL-2.
Latent myostatin can undergo an additional stage of proteolytic processing.
Members of the BMP-1/tolloid family of metalloproteinases have been implicated in this process, including BMP-1, TLL-1 and TLL-2.
These enzymes can cleave the myostatin prodomain.
Disruption of the prodomain-mature ligand complex makes mature myostatin more available for receptor interaction.
This creates an important distinction in experimental research.
Researchers can investigate the amount of myostatin produced, but they can also examine the processes controlling how much of that myostatin becomes available in an active form.
Why Does the Myostatin Prodomain Matter?
The prodomain is not simply a discarded component of the original precursor.
After initial cleavage, it continues to interact with mature myostatin and contributes to maintaining the latent complex.
Researchers have therefore investigated several aspects of prodomain biology, including its structure, interaction with mature myostatin and susceptibility to proteolytic cleavage.
This provides an experimental control point upstream of receptor signalling.
Rather than examining only what happens after mature myostatin becomes available, researchers can investigate the molecular events that regulate its release from latency.
What Regulates Myostatin Outside the Cell?
Proteolytic activation is not the only factor affecting extracellular myostatin availability.
Several endogenous proteins can interact with myostatin or related TGF-β-superfamily ligands.
These interactions form part of a wider extracellular regulatory network.
Among the proteins studied in this context are:
- follistatin
- follistatin-like 3
- GASP-family proteins
- the myostatin prodomain itself
These molecules do not all behave in the same way, nor are they necessarily specific to myostatin.
That distinction is important when interpreting experiments designed to alter myostatin activity.
How Does Follistatin Relate to Myostatin?
Follistatin can bind myostatin and restrict its availability, but it also interacts with other TGF-β-superfamily ligands and is not specific to myostatin.
Follistatin is an extracellular binding protein that interacts with several members of the TGF-β superfamily.
Myostatin is one of those ligands.
Binding can restrict the availability of a ligand for receptor interaction, which has made follistatin useful in experiments examining extracellular regulation.
However, describing follistatin simply as a “myostatin blocker” would be incomplete.
Follistatin also interacts with other ligands, including activins.
An experimental response observed after altering follistatin activity therefore cannot automatically be attributed exclusively to myostatin.
What Is FSTL3?
Follistatin-like 3, usually abbreviated FSTL3, is another extracellular binding protein investigated in relation to myostatin and activin-family signalling.
Despite its name, FSTL3 is not identical to follistatin.
The proteins differ structurally and can display different binding characteristics.
Comparative experiments involving follistatin and FSTL3 can therefore help researchers examine how different extracellular regulators influence ligand availability.
Again, specificity needs to be considered when interpreting the results.
What Are GASP Proteins?
Growth and differentiation factor-associated serum proteins, or GASP proteins, form another part of the extracellular regulatory environment.
GASP-1 has been investigated for its interactions with myostatin and related growth factors.
These interactions add another layer of regulation between production of the myostatin protein and its eventual interaction with cell-surface receptors.
The presence of these regulators also illustrates why MSTN gene expression alone cannot describe the complete state of the myostatin system.
Protein processing, activation and extracellular interactions all contribute additional information.
What Does Myostatin Inhibition Mean in Research?
Myostatin inhibition describes experimental approaches that interfere with specific stages of myostatin processing, activation, ligand availability or receptor interaction.
Myostatin inhibition does not describe one experimental technique. Researchers can interfere with different stages of the pathway, and the molecular target determines what an experiment can establish.
Preventing Latent Myostatin Activation
One approach is to interfere with the conversion of latent myostatin into its active form. This allows researchers to examine extracellular activation separately from myostatin production.
Binding Mature Myostatin
Other experimental approaches investigate molecules that interact with mature myostatin. These studies examine ligand availability after activation has occurred.
Investigating Endogenous Binding Proteins
Follistatin, FSTL3 and other extracellular proteins can also be used to study ligand regulation. Because some of these proteins interact with additional TGF-β-superfamily members, experimental findings may not be specific to myostatin.
Interfering With Receptor-Level Activity
Researchers can also investigate receptor interactions. Since receptor systems may be shared by multiple ligands, selectivity remains an important consideration.
Why Does Selectivity Matter?
Myostatin belongs to a large family of related signalling proteins.
Some of these proteins interact with the same extracellular regulators or receptor systems.
An experimental intervention may therefore influence more than one signalling molecule.
Follistatin provides one example because it interacts with several ligands.
Receptor-level experiments create a similar issue because a receptor used by myostatin may also recognise other members of the same protein family.
Researchers therefore need to distinguish between:
- selective myostatin interventions
- interventions affecting several ligands
- interventions affecting shared receptors
Without that distinction, it can be difficult to determine which molecular interaction produced an observed result.
Why Is Latent Myostatin Useful in Experimental Research?
Latent myostatin provides researchers with a way to investigate regulation before receptor interaction occurs.
Several questions can be examined at this stage.
How efficiently is the precursor processed?
How stable is the latent complex?
Which enzymes participate in prodomain cleavage?
How does changing that cleavage affect the availability of mature ligand?
These experiments help separate myostatin production from myostatin activation.
That is important because the presence of the protein does not necessarily indicate that the same amount is available in an active form.
How Do Researchers Distinguish Different Forms of Myostatin?
Researchers use analytical and functional methods that can distinguish or characterise precursor, latent and mature myostatin, depending on the molecular form and activity being investigated.
Different analytical methods provide different information.
Antibody-based assays may recognise particular regions of the myostatin molecule. Depending on antibody specificity, this can influence which molecular forms are detected.
Protein-separation methods can help distinguish molecules according to characteristics such as size.
Mass spectrometry can provide additional structural information about proteins and peptides present in a sample.
Functional assays address a different question by examining biological activity rather than simply measuring protein abundance.
Researchers therefore need to consider exactly what an assay detects before comparing “myostatin levels” between experiments.
Why Can Myostatin Studies Produce Different Findings?
Two studies may both investigate myostatin inhibition while targeting different stages of the molecular pathway.
One experiment might examine mature myostatin, while another focuses on latent activation or an extracellular binding protein. These approaches do not answer precisely the same question.
Differences in molecular target, experimental system, intervention duration, selectivity, analytical method and the form of myostatin being measured can all influence the findings.
For this reason, the term "myostatin inhibition" is most useful when the specific experimental mechanism is also identified.
What Can Myostatin Research Tell Us?
Research has established a molecular framework for investigating how myostatin is produced and regulated.
Scientists can examine precursor processing, latent-complex formation, extracellular activation and endogenous binding proteins as separate experimental variables. This allows individual parts of the system to be studied without treating myostatin activity as a single event.
It is still important to have an experimental context; although both an intervention which affects latent activation and one which involves a shared extracellular regulator may lead to changes in myostatin-associated measurements, the two act at different points in the pathway.
Findings therefore need to be interpreted according to the molecular target and experimental system involved.
What Does the Current Evidence Establish?
Research has established that myostatin is regulated through several distinct molecular stages.
The protein is produced as a precursor before undergoing processing and formation of a latent complex. Additional extracellular events influence the availability of mature myostatin, while endogenous binding proteins provide further regulatory mechanisms.
Researchers can investigate these processes through activation-focused experiments, ligand-interaction studies, biochemical assays and studies of extracellular regulators. These approaches are related, but they are not equivalent.
Understanding where an experimental intervention acts is therefore essential when comparing findings across the myostatin literature.
The evidence provides a framework for investigating myostatin processing, activation and extracellular regulation. It does not establish the safety, efficacy or suitability of myostatin-targeting research materials for human use.
Myostatin Research: Key Points
The study of myostatin involves more than just the presence of GDF-8. Scientists examine how the protein is produced, how it is kept in a latent state, how it is activated by processing outside the cell, and how it is regulated by binding proteins. Since experimental inhibition can act at different stages of this process, the findings have to be understood in the context of the particular molecular target and the research model employed.
Frequently Asked Questions About Myostatin Regulation and Inhibition
After the precursor has been processed, the mature myostatin still remains bound to its prodomain, which limits the availability of the ligand until further molecular processing takes place.
Research has implicated BMP-1/tolloid-family metalloproteinases, including BMP-1, TLL-1 and TLL-2, in prodomain cleavage associated with the activation of latent myostatin.
No. Experimental assays may detect precursor, latent or mature forms of myostatin, so total protein measurements do not necessarily indicate the amount of biologically available ligand.
Genetic disruption, inhibition of latent activation, mature-ligand binding and receptor-level interventions act at different stages of myostatin biology and therefore address different experimental questions.
Not necessarily. Follistatin interacts with several TGF-β-superfamily ligands, including activins, so experimental findings cannot automatically be attributed exclusively to myostatin.
The prodomain helps maintain myostatin in a latent state, making its structure, interactions and proteolytic processing relevant to research into the control of mature ligand availability.
Scientific references
- 1 Lee SJ. Extracellular Regulation of Myostatin: A Molecular Rheostat for Muscle Mass. Immunol Endocr Metab Agents Med Chem. 2010;10:183-194. doi: 10.2174/187152210793663748. https://pmc.ncbi.nlm.nih.gov/articles/PMC3060380/
- 2 Walker RG, McCoy JC, Czepnik M, Mills MJ, Hagg A, Walton KL, Cotton TR, Hyvönen M, Lee RT, Gregorevic P, Harrison CA, Thompson TB. Molecular characterization of latent GDF8 reveals mechanisms of activation. Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E866-E875. doi: 10.1073/pnas.1714622115. https://pmc.ncbi.nlm.nih.gov/articles/PMC5798348/
Research-use disclaimer: For research and laboratory use only. Not for human or animal consumption.
